Business Wire

EFPIA

13.5.2022 06:02:05 CEST | Business Wire | Press release

Share
Boosting Cardiovascular Health in Europe – Towards More Resilient and Equitable Healthcare

More than two years after the COVID-19 pandemic started, healthcare systems are taking stock of the lessons learnt to strengthen their response and improve the health outcomes of patients across disease areas. In this context, the European Federation of Pharmaceutical Industries and Associations (EFPIA) CVD Network commissioned a report in collaboration with PwC on “Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare” , to assess the impact of COVID-19 on cardiovascular (CVD) care and to explore possible policy actions to strengthen the healthcare systems’ response to CVDs.

The report finds that:

  • Cardiovascular disease (CVD) is the major cause of mortality and morbidity across Europe, affecting almost 95 million patients and, notably causing 1.24 million acute coronary events each year.
  • CVD accounts for almost one-third of all premature deaths and is responsible for 23 % of all disability-adjusted life years (DALYs) measured across Europe, exceeding the burden caused by all other non-communicable diseases (NCDs), including cancer.
  • At the same time, many CVDs are preventable or, at least, manageable with appropriate interventions, often more so than other major NCDs. Overall, about 70% of the CVD burden is attributable to risk factors that can be controlled or modified, such as hypertension, high cholesterol or diabetes.
  • COVID-19 has made things worse. The pandemic has increased the risk of hospitalisation and death for people with CVD and put healthcare systems under strain, disrupting detection and care pathways and exposing existing disparities in CVD care.
  • Short-term shocks, similar to the pandemic, are likely to become more frequent, thus boosting healthcare demand, and stretching healthcare services even further.
  • Evolving disease patterns will force healthcare systems to reshape their care delivery models. With 130 million Europeans expected to be over the age of 65 by 2050, CVD-related healthcare demand is bound to grow and transform over the coming decades.

Following the findings, the report offers a series of concrete policy recommendations that aim to re-design CVD care and equip European healthcare systems with the necessary tools to cope with future crises:

  • Strengthen population screening
    • Broaden screening programmes for genetic and metabolic risk factors
    • Simplify access to screening, especially for vulnerable populations
  • Ensure treatment initiation, maintenance, and follow-up for at-risk patients
    • Re-design healthcare systems to reward outcomes
    • Strengthen digital health and information sharing to improve disease management
  • Foster data-driven decision making
    • Harness the potential of data-driven solutions to inform CVD policies and support clinical decision-making and value-based care delivery

Cardiovascular diseases are Europe’s biggest health challenge. The time to act is now. Building on the available evidence, we need bold policy action for better population health in Europe ” commented Christian Thonke and Sean Lybrand, co-Chairs of the EFPIA CVD Network.

The Report calls on all CVD stakeholders to play their part in advancing CVD prevention, detection and care, by putting the spotlight on secondary prevention and encouraging a smarter use of digital technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release

Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye